Alzinova (STO:ALZ) First Quarter 2025 Results
Key Financial Results
- Revenue: kr6.09m (up 114% from 1Q 2024).
- Net loss: kr5.68m (loss widened by 14% from 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Alzinova Earnings Insights
Looking ahead, revenue is expected to decline by 35% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Sweden are expected to grow by 16%.
Performance of the Swedish Biotechs industry.
The company's shares are down 6.3% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Alzinova has 5 warning signs (and 2 which shouldn't be ignored) we think you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:ALZ
Alzinova
A biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden.
Excellent balance sheet moderate.
Market Insights
Community Narratives
